

CURRICULUM VITAE

William D. Dupont, Ph.D.

March 12, 2009

PRESENT POSITION

Professor of Biostatistics and Preventive Medicine

Address: Department of Biostatistics
S-2323 Medical Center North
Vanderbilt University School of Medicine
Nashville, Tennessee 37232-2158

Telephone: (615) 343-4100
Facsimile: (615) 343-4924
E-Mail: william.dupont@vanderbilt.edu

Web Page: <http://biostat.mc.vanderbilt.edu/WilliamDupont>

PERSONAL

Born: Montreal, Quebec, Canada
Citizenship: Dual Canadian / U.S. Citizenship:
Wife: Susan McChesney Dupont
Children: C. Thomas
Peter W.

EDUCATION

1964 – 1969 B.Sc. — Mathematics
McGill University, Montreal, QC, Canada
1969 – 1971 M.Sc. — Mathematics
McGill University, Montreal, QC, Canada
1971 – 1977 Ph.D. — Biostatistics
The Johns Hopkins University, Baltimore, MD

ACADEMIC DISTINCTIONS AND AWARDS

B.Sc. granted with Great Distinction in the General Course and Major in Mathematics.

2003 Earnest W. Goodpasture Award – with David L. Page for collaborative studies that address important biological problems and their role in disease pathogenesis

ACADEMIC APPOINTMENTS

1976 – 1977	Lecturer University of Maryland in Baltimore County
1977 – 1985	Assistant Professor of Preventive Medicine (Biostatistics) Vanderbilt University School of Medicine
1986 – 1992	Associate Professor of Preventive Medicine (Biostatistics with tenure) Vanderbilt University School of Medicine
1989 – 2003	Director, Division of Biostatistics Vanderbilt University School of Medicine
1992 – present	Professor of Preventive Medicine (Biostatistics) Vanderbilt University School of Medicine
1994 – 1997	Director, Biostatistics/Data Management Shared Resource Vanderbilt Cancer Center Vanderbilt University School of Medicine
2003 – present	Professor of Biostatistics Vanderbilt University School of Medicine

TEACHING

1. At Vanderbilt

Courses Given

- i.) Medical Statistics (PM 502): Taught 1978 – 1980.
- ii.) The Analysis of Failure Time Data (BIOS 294): Taught 1980.
- iii.) Biostatistics 2 (514-5509) Course on generalized linear models, survival analysis and analysis of variance given in the M.P.H Program, 1997, 1999, and 2001 – 2009.

Lectures and Seminars

- i.) Lectures in Epidemiology for Engineering Students (EWRE 327): A series of 3 lectures given in 1978 – 1982.
- ii.) The Design and Analysis of Electrocardiographic Experiments: Clinical Pharmacology seminar, 1978.
- iv.) Statistical Power and Sample Size Calculations: Department of Surgery seminar, 1981.
- v.) Analyzing Data from Clinical Trials: Clinical Pharmacology seminar, 1981.
- vi.) Principles of Public Health and Preventive Medicine (PM 503): Gave lectures on case control studies and on clinical trials. Led discussion groups on these and other topics, 1984.
- vii.) Cancer, Basic Concepts (Path 5210): Gave introductory lecture on cancer epidemiology, 1984.
- viii.) Fundamentals of Clinical Trials (MED 533): Gave lecture on hypothesis testing, statistical inference, and sample size calculations for clinical trials, 1984.
- ix.) Principles of Epidemiology, Biostatistics and Preventive Medicine (PM 501): Organized a three-week section on cancer epidemiology. Gave lectures on population based studies, case-control studies, and cohort studies. Introduced concepts of hypothesis testing, statistical power, and sample size determination, 1985 – 1987, 1999. Gave lectures on clinical trials, 1988, 1995 – 1997; statistical inference, 1988, 1989, 1996, and 1997; screening for cancer, 1990. Led group sessions on these topics, 1991 – 1998, 1999, 2002.
- x.) Epidemiology of Breast Cancer: Obstetrics and Gynecology Grand Rounds given with D.L. Page, 1986. Broadcast on the VMT television network and published on video cassette.
- xi.) Risk Factors for Breast Cancer in Women with Proliferative Breast Disease: Preventive Medicine seminar, 1986.
- xii.) Sample Size Estimation in Matched Case-Control Studies: Preventive Medicine seminar, 1987.
- xiii.) Controversies in Clinical Trials: Cardiology seminar, 1987.
- xiv.) Introduction to Survival Analysis: Center for Fertility and Reproductive Research Seminar, 1988.
- xv.) Does Replacement Estrogen Increase the Risk of Breast Cancer?: Preventive Medicine Research Conference, 1989.
- xvi.) What Are the Frontiers of Research in Benign Breast Disease?: Preventive Medicine Research Conference, 1989.

- xvii.) Some Common Statistical Errors in the Medical Literature: Clinical Pathology Conference, 1990.
- xviii.) Model for Continuous Data with Constant Variance: Seminar on Chapter 3 from McCullagh and Nelder, *Generalized Linear Models*, given to the Middle Tennessee Chapter of the American Statistical Association, 1990.
- xix.) Models for Survival Data: Seminar on Chapter 13 from McCullagh and Nelder, *Generalized Linear Models*, given to the Middle Tennessee Chapter of the American Statistical Association, 1990.
- xx.) Two-Stage Linear Models: Seminar on Chapter 6 from Crowder and Hand, *Analysis of Repeated Measures*, given to Middle Tennessee Chapter of the American Statistical Association, 1991.
- xxi.) Breast Cancer Risk Associated with Proliferative Breast Disease and Atypical Hyperplasia: Preventive Medicine Research Conference, 1992.
- xxii.) An Overview of Meta-Analysis: Methods for Reviewing Medical Literature: Preventive Medicine Research Conference, 1993.
- xxiii.) Understanding (explaining) the Relationship Between Relative and Absolute Risk: Preventive Medicine Research Conference, 1995.
- xxiv.) Lies, Damn Lies, and Statistics: Pediatric Neonatology Seminar, 1995.
- xxv.) Hormone Replacement Therapy and Breast Cancer: Breast Cancer Training Grant (L.M. Matrisian, P.I.), December 1995.
- xxvi.) The Pros and Cons of Hormonal Replacement Therapy: Preventive Medicine Seminar, November 1997.
- xxvii.) Estrogen Replacement Therapy in Women with a History of Proliferative Breast Disease: Preventive Medicine Conference, December 1997.
- xxviii.) A Brief Introduction to Logistic Regression and Survival Analysis: Can You Survive This Regression? Pulmonary Medicine Seminar, March 1999.
- xxix.) Transforming Growth Factor- β Type II Receptors and Breast Cancer Risk in Women with Mammary Epithelial Hyperplasia: Preventive Medicine Seminar, January, 2000, also given to the Vanderbilt Program in Human Genetics, February 2000.
- xxx.) How to calculate sample size and statistical power using the PS software program. GCRG Research Skills Workshop, May 2002.
- xxxi.) TGF- β 1 T29 \rightarrow C Polymorphism and Breast Cancer Risk in Women with and without Proliferative Disease: VICC Breast Cancer Program Seminar, October 2003.
- xxxii.) How to use the sample size software PS for survival analyses and complex study designs. GCRG Research Skills Workshop, October 2003.

- xxxiii.) Using Density Distribution Sunflower Plots for the Display of Dense Bivariate Data. Biostatistics Seminar. August 2004.
- xxxiv.) Introduction to Logistic Regression. GCRC Research Skills Workshop Series. November, 2004.
- xxxv.) Some considerations for using PS sample size software. M.S. Biostatistician's Workshop, March, 2006
- xxxvi.) The Conditionality Principle and 2x2 Contingency Tables: Some Thoughts on the Foundations of Statistical Inference: Part I. Biostatistics Seminar given with Leena Choi, April 2006.
- xxxvii.) The Conditionality Principle and 2x2 Contingency Tables: Some Thoughts on the Foundations of Statistical Inference: Part II. Biostatistics Seminar given with Leena Choi, April 2006.
- xxxviii.) How to do Power & Sample Size Calculation - Part 1. GCRC Research Skills Workshop Series. October, 2007.
- xxxix.) How to do Power & Sample Size Calculation - Part 2. GCRC Research Skills Workshop Series. October, 2007.
- xl.) Introduction to Power and Sample Size Calculations. Department of Pathology Seminar. November 2007.

2. At Other Universities

Courses Given

- i) Introduction to Statistics for Social Scientists. (Math 0121, University of Maryland): Taught 1976, 1977.
- ii) Ideas in Mathematics (Math 0100, University of Maryland): Taught 1977.

Lectures and Seminars

- iii) Comparing Low Mortality Rates in Longitudinal Censored Observational Data. Seminar given at Johns Hopkins University in 1979.
- iv) The Analysis of Cohort Data in Ecologic Statistics. Seminar given at Utah State University and Johns Hopkins University in 1980.
- v) Principles of Data Management for Ecologists. Seminar given at Utah State University, 1981.
- vi) A Stochastic Catch-Effort Method for Estimating Animal Abundance. Seminar given at Johns Hopkins University in 1982 and at the Savannah River Ecology Laboratory in 1985.

- vii) Risk Factors for Breast Cancer in Women with Proliferative Breast Disease. Seminar given at the Université de Montpellier, France, and at the Certificat International des Maladies du Sein, Paris, France, 1986.
- viii) Power Calculations for Matched Case-Control Studies. Seminar given at Johns Hopkins University in 1987.
- ix) Premalignant Markers of Increased Breast Cancer Risk. Seminar given at the National Institute of Environmental Health Sciences, 1992.
- x) Understanding (explaining) the Relationship Between Relative and Absolute Risk. Seminar given at the Memorial Sloan-Kettering Cancer Institute, New York, NY, 1995.
- xi) The Relationship of Proliferative Changes and Fibroadenoma to Breast Cancer Risk. Pathology Grand Rounds. St. Barnabas Medical Center, Livingston, NJ, 1995.
- xii) L'Oestrogénothérapie Substitutive et le Risque de Cancer du Sein. Seminar given at the Institut Paoli-Calmettes, Marseille, France, 1995.
- xiii) Les Mastoses Prolifératives, les Adénofibrome et le Risque de Cancer du Sein. Seminar given at the Institut Paoli-Calmettes, Marseille, France, 1995.
- xiv) Benign Breast Diseases, Hormonal Replacement Therapy and Breast Cancer Risk. Centro de Estudos Olinto de Oliverira Instituto Fernandis Figueira Rio de Janeiro, Brazil, June 1995.

CURRENT RESEARCH AT VANDERBILT

1. Conducting epidemiologic studies of genetic, molecular and histologic risk factors for breast cancer (with D.L. Page, J.R. Smith, F.F. Parl and M.E. Sanders).
2. Working with B.W. Christman (Allergy / Pulmonary and Critical Care Medicine) on a clinical trial of Citrulline to prevent hepatic toxicity in patients undergoing bone marrow transplant.
3. Working with T.V. Hartert (Allergy / Pulmonary and Critical Care Medicine) on studies on risk factors for asthma in children.
4. Working with D. Robertson (Clinical Pharmacology Division/Medicine) on studies of Autonomic Cardiovascular Regulation.

GRANTS RECEIVED AS PRINCIPAL INVESTIGATOR

1. An Epidemiologic Study of Breast Cancer Risk Factors. NCI grant #RO1 CA 28223-01, 1980 – 81. \$39,773 awarded for direct costs.
2. The Effect of Lobular Atrophy on Breast Cancer Risk in Women Who Have Undergone Benign Breast Biopsies. Biomedical Research Support Grant #RR-05424, 1981. \$2,500 awarded.

3. Epidemiology of Breast Cancer Risk After Fibroadenoma. NCI grant #RO1 CA31698, 1982 – 1985. \$379,280 awarded for direct costs in 1982 – 85.
4. Breast Cancer Risk Associated with Fibroadenomas and Other Histologic and Epidemiologic Risk Factors. Biomedical Research Support Grant #RR-05424-24, 1985. \$5,806 awarded.
5. Lopressor in Myocardial Infarction Trial. 1986 – 1988 Contract from CIBA-GEIGY Corporation for \$55,514 to build and analyze a patient database from a multi-center clinical trial.
6. Breast Cancer Risk After Atrophic or Apocrine Changes. NCI grant #RO1-CA40517, 1986 – 1989. \$600,752 awarded for 1986 – 1989.
7. Breast Cancer in Women with Proliferative Breast Disease. NCI grant #RO1-CA46492, 1988 – 1991. \$454,638 awarded for 1988 – 1991.
8. Epidemiology of Molecular Risk Factors for Breast Cancer. NCI grant #RO1- CA50468, 1990 – 2008. \$8,742,211 awarded. Recommended additional funding through 2011, \$1,881,591.

GRANT SUPPORT RECEIVED AS CO-INVESTIGATOR

1. SCOR in Hypertension, NHLBI grant #HL-14192, 1977 – 1995.
2. Risk Associated with the Diagnosis of Non-Invasive Mammary Carcinoma and Pre-Cancerous Mammary Hyperplasias. NCI grant #CB74098, 1977 – 1980.
3. Professional Oncology Education Program, NCI grant #2 R25 CA 19429-09, 1984 – 1987.
4. Efficacy of Cold Adapted Influenza Vaccine. NIAID Contract #N01-AI-52593, 1985 – 1991.
5. Cardiopulmonary Effects of Ibuprofen in Human Sepsis. NHLBI grant #RO1-HL-43167, 1990 – 1995.
6. SCOR in Acute Lung Injury, 5P50 grant #HL19153, 1995 – 1998.
7. Mechanisms of Post Bone Marrow Transplantation Lung Injury. NIH/NHLB(HL) grant #1R01 HL55198, 1995 – 1999.
8. Patient Care Provider Order Entry with Tactical Support. NIH grant #1R01 LM06226-01A1, 1997 – 2000.
9. Etiology of Early Breast Malignancy. NCI grant #R01-CA72025, 1996 – 2000.
10. Autonomic Cardiovascular Regulation. NIH grant #1P01-HL56693, 1997 – 2009.
11. Chemotherapy Toxicity: Reduction in the Urea Cycle Support. NIH/NCI grant #5R01-CA92313, 2001 – 2006.
12. SPORE in Breast Cancer. NCI grant #P50 CA098131, 2003-2009. Project Co-leader for Project 4: “Molecular Epidemiology of Proliferative Breast Disease”.

13. The Vanderbilt Institute for Clinical and Translational Research (VICTR) NCCR grant #UL1 RR024975, 2007 – 2008.
14. Maternal and Infant Effects of Treated and Untreated Depression during Pregnancy. NIMH grant #R03 MH077902, 2007 – 2008.
15. Dietary Antioxidants and Incidence of Adult-onset Asthma. NIAID grant #R02 AI50884, 2007 – 2008.
16. MCC and VICC Partners in Eliminating Cancer Disparities. NCI grant #U54 CA091405, 2007 – 2008.
17. Asthma Disparities in Cohorts at Risk for Morbidity. NHLBI grant #U01 HL072471, 2006 – 2008.
18. The Nashville Breast Health Study. NIH grant #R01 CA100374, 2007 – 2009.
19. Dopamine-B-Hydroxylase in Human Cardiovascular Control. NHLBI grant # R01 HL071784, 2008 – 2009.

ACADEMIC SERVICE

1. Has refereed papers for the following journals:
 - i) *American Statistician*
 - ii) *American Journal of Epidemiology*
 - iii) *American Journal of Obstetrics and Gynecology*
 - iv) *American Journal of Public Health*
 - v) *Breast*
 - vi) *Biometrical Journal*
 - vii) *Biometrics*
 - viii) *Cancer*
 - ix) *Cancer Causes and Control*
 - x) *Cancer Research*
 - xi) *Clinical Pharmacology & Therapeutics*
 - xii) *Computer Methods and Programs in Biomedicine*
 - xiii) *Controlled Clinical Trials*
 - xiv) *Drug Safety*
 - xv) *European Journal of Cancer and Clinical Oncology*
 - xvi) *Human Pathology*
 - xvii) *International Journal of Cancer*
 - xviii) *International Journal of Epidemiology*
 - xix) *Journal of Andrology*
 - xx) *Journal of the National Cancer Institute*
 - xxi) *Journal of Wildlife Management*
 - xxii) *Menopausal Medicine*
 - xxiii) *New England Journal of Medicine*
 - xxiv) *Radiation Effects Research Foundation Technical Reports*

xxv) *Southern Medical Journal*
 xxvi) *Stata Journal*
 xxvii) *Statistics in Medicine*

2. Member of the Graduate Faculty Delegate Assembly at Vanderbilt University, 1979 – 1982.
3. Co-Chairman, local arrangements committee, 1983 Spring meetings of the Biometric Society (Eastern North American Region) in Nashville.
4. Member of the Clinical Research Center Advisory Committee, 1985 – 1987.
5. Acting Director of the Division of Biostatistics, 1987 – 1988.
6. Member of the Medical Center Quality Care Committee, 1987 – 1989.
7. Member of the National Cancer Institute's Breast Cancer Working Group, 1988 – 1990.
8. American Cancer Society referee for postdoctoral fellowship applications, 1989.
9. Participated in the NCI Breast Cancer Progress Review Group, Baltimore, MD, 1997.
10. Member of the Cancer Prevention Research Program, Vanderbilt Cancer Center, 1998 - Present.
11. Member of the Bioinformatics Faculty Recruitment Task Force, 1999 - Present.
12. Member of the American Joint Committee on Cancer: Statistics Committee, 2000 – present.
13. Member of the Faculty Appointments and Promotions Committee of School of Medicine of Vanderbilt University School of Medicine, 2003 – present.

MEMBERSHIP IN Ph.D. THESIS COMMITTEES AND STUDENT MENTORING

- L. Renee Bailey, PhD. Pathology, 1996 – 1998
 PhD thesis "Genetic Susceptibility and Carcinogen Metabolism in Breast Cancer Molecular Epidemiology"
 Role: PhD Advisory Committee member
- S. Trent Rosenbloom, MD, MPH. 2001 – 2002
 MPH thesis "Patterns of Serum Magnesium Testing at Vanderbilt University Medical Center"
 Role: MPH mentor
- Brian Yaspan, MPH, Cancer Biology, 2002 – 2008
 PhD Thesis "Genetic Predisposition to Prostate Cancer: The Contribution of the HPCX locus and TGFBI gene"
 Role: PhD Advisory Committee member

Kecia N. Carroll, MD, MPH, FAAP 2007 – present
 Role: Mentoring Committee member

MEMBERSHIP IN DATA MONITORING BOARDS

1. Effect of Polyunsaturated Lecithin on Liver Fibrosis. Department of Veterans Affairs Cooperative Study #391, Baltimore, MD, 1994 –2000.

EDITORIAL ADVISORY BOARDS

1. *Cancer*, 1995 – 2003
2. *The Breast*, 1996 – 2008

ASSOCIATE EDITORSHIPS

1. *Stata Journal*, 2004 – present

MEMBERSHIP IN NIH STUDY SECTIONS AND REVIEW COMMITTEES

1. *Epidemiology and Disease Control Study Section-2*
 - i) October 12 – 14, 1988
 - ii) February 5 – 8, 1991
 - iii) October 19 – 21, 1992
 - iv) February 3 – 5, 1993
 - v) March 18 – 19, 1996
2. *Epidemiology and Disease Control Study Section-1*
 - i) August 9, 1988
 - ii) December 15, 1988
 - iii) March 29, 1989
3. *Subcommittee E- Cancer Epidemiology, Prevention and Control*
 - i) August 4, 2004
 - ii) September 29, 2004
4. *Geriatrics and Rehabilitation Study Section*
 - i) February 21, 1995
5. *Special Study Section for Small Grants in Epidemiology*
 - i) April 19, 1989
 - ii) August 8, 1989
 - iii) December 4, 1990

6. *RFP Reviews*

- i) June 28, 1990, NIAID
- ii) April 12, 1992, NICHD

7. *Special Review or Study Section*

- i) April 21, 1988
- ii) November 16, 1988
- iii) April 28, 1994
- iv) January 13, 1998

8. *NCI Special Emphasis Panel*

- i) November 2002, Community Clinical Oncology Program Grant Review
- iii) July 2003, Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults

9. *NCI Initial Review Group: Subcommittee H – Clinical Groups*

- i) October 26-28, 2003, Review of the Gynecologic Oncology Group grant application
- ii) October 13,14, 2008 Review of Cancer and Leukemia Group B (CALGB) grant application

10. *Site Visit Committees*

- i) March 20 – 21, 1991, Harvard University, NCI Special Review.
- ii) January 29, 1993, University of Texas, EDC-2.
- iii) November 16 – 18, 1994, Columbia University, NCI, Breast Cancer and the Environment of Long Island.
- iv) October 22 – 24, 1995, Harvard University, NCI Special Review.
- v) October 6 – 8, 1997, Johns Hopkins University, NCI Review Panel.
- vi) March 11-13, 1998, Cleveland Clinic Cancer Center, NCI Review Panel.
- vii) May 20-22, 1998, Fred Hutchinson Cancer Research Center, NCI Review Panel.
- viii) June 17, 1998, Johns Hopkins University, NCI Review Panel (telephone review of revised application)
- ix) September 15-16, 2003, Roswell Park Cancer Institute, Buffalo, New York: NCI Review Panel for the Gynecologic Oncology Group Statistical and Data Center.

PROFESSIONAL SOCIETIES

- 1. *American Statistical Association, 1975 – present*
- 2. *Biometric Society, 1974 – present*
- 3. *Society for Clinical Trials, 1980 – present*
- 4. *Society for Epidemiologic Research, 1985 – 1994*
- 5. *American Association for the Advancement of Science, 1987 – 2003*

CONTINUING EDUCATION — SHORT COURSES ATTENDED

1. The Statistical Analysis of Failure Time Data. Given by J.D. Kalbfleisch and R.L. Prentice. Toronto, ON, 1981.
2. Advanced Statistical Methods in Epidemiology. Given by N.E. Breslow, N.E. Day, D. Claton, and J. Kaldor. University of Washington, Seattle, WA, 1988.
3. Short Course on Meta-Analysis. Given by T. Chalmers and I. Olkin. Sponsored by the Centers for Disease Control. Atlanta, GA, 1993.
4. Statistical Methods for Genetic Epidemiology. Given by Robert C. Elston and Daniel J. Schaid. Biometric Society Spring Meetings. Cleveland, OH, 1994.
5. Visualizing Data with Trellis Graphics. Given by Stephen Kaluzny. The International Biometric Society (ENAR) Meeting. Memphis, TN, March, 1997.
6. Writing Mixed models and SAS PROC MIXED for Repeated Measures and Random Effects Data. Given by R. D. Wolfinger. The International Biometric Society (ENAR) Meeting. Memphis, TN, 1997.
7. Statistical Analysis with Missing Data. Given by R.J.A. Little and T.E. Raghunathan. The International Biometric Society (ENAR) Meeting. Pittsburgh, PA, 2004.
8. Modeling and Analysis of Categorical Data with Overdispersion. Given by Jorge Morel and Nagaraj Neerchal. Joint Statistical Meetings. Toronto, Ontario Canada. 2004.
9. Power and Sample Size Analysis Using New SAS/STAT Software. Given by John Castelloe. Joint Statistical Meetings. Toronto, Ontario Canada. 2004.
10. Statistical Genetics. Given by Kenneth Lange, Janet Sinsheimer and Eric Sobel. Joint Statistical Meetings. Salt Lake City, Utah.

PAPERS PRESENTED AT PROFESSIONAL MEETINGS

1. **Dupont WD:** Estimating animal abundance from catch-effort data. Eastern Regional Meetings of the American Statistical Association, Chapel Hill, NC, April 1977.
2. **Dupont WD:** Comparing low mortality rates in longitudinal censored observational data. Joint Statistical Meetings of the American Statistical Association and the Biometric Society, Washington, DC, August 1979. *Biometrics*, 1980; 36:736.
3. **Dupont WD:** Choosing the best P value for clinical trials. Society for Clinical Trials, Philadelphia, PA, May 1980. *Controlled Clin Trials*, 1980; 1:171.
4. **Dupont WD** and Wright RF: An interactive data quality assurance program. Society for Clinical Trials, San Francisco, CA, May 1981. *Controlled Clin Trials*, 1981; 2:81.

5. **Dupont WD:** A hazard regression method for estimating animal abundance from catch-effort data, (an invited paper). Joint Statistical Meetings of the American Statistical Association and the Biometric Society, Detroit, MI, August 1981.
6. **Dupont WD:** Fisher's exact test and the magically shrinking P-value. Joint Statistical Meetings of the American Statistical Association and the Biometric Society, Detroit, MI, August 1981.
7. **Dupont WD, Wright RF, and Plummer WD:** A sequential log rank test. Society for Clinical Trials, Pittsburgh, PA, May 1982. *Controlled Clin Trials*, 1982; 3:139.
8. **Dupont WD and Page DL:** Histologic predictors of breast cancer: epidemiologic and statistical aspects, (an invited paper). 26th Annual Clinical Conference of the University of Texas M.D. Anderson Hospital and Tumor Institute, Houston, TX, November 1982.
9. **Dupont WD and Page DL:** A retrospective cohort study of women with benign breast disease: Interactions between histologic and other factors on breast cancer risk. Society for Epidemiologic Research, Chapel Hill, NC, June 1985. *Am J Epidemiol*, 1985; 122:516.
10. **Dupont WD:** Epidemiology of benign breast lesions and the risk for cancer (an invited paper). Conference sponsored by the College of American Pathologists entitled Is 'Fibrocystic Disease' of the Breast Precancerous? New York, NY, October 1985.
11. **Dupont WD:** Converting relative risks to absolute risks: a graphical approach for breast cancer and heart disease. Society for Clinical Trials, Montreal, QC, May 1986. *Controlled Clin Trials*, 1986; 7:238.
12. Antman E, Califf RM, Danforth JW, **Dupont WD**, and other panel discussants, L.I.M.I.T./Supplemental U.S. Trials. Symposium on the Treatment of Acute Myocardial Infarction sponsored by CIBA-GEIGY Corporation, Maui, HI, September 1986.
13. **Dupont WD and Page DL:** Influence of exogenous estrogens, proliferative breast disease and other variables on breast cancer risk. Society for Epidemiologic Research, Amherst, MA, June 1987. *Am J Epidemiol*, 1987; 126:735.
14. **Dupont WD and Page DL:** Determining precursor lesions for human cancers: A methodologic overview, (an invited paper). Society for Epidemiologic Research. Vancouver, BC, June 1988. *Am J Epidemiol*, 1988; 128:945.
15. **Dupont WD, Page DL, Parl FF, Rados MA, and Plummer WD:** Breast cancer risk associated with fibroadenomas. Society for Epidemiologic Research, Vancouver, BC, June 1988. *Am J Epidemiol*, 1988; 128:914, *Laboratory Investigation*, 1990; 62:28A.
16. **Dupont WD:** Power calculations for matched case-control studies. Joint Statistical Meetings. New Orleans, LA, August 1988.

17. **Dupont WD** and Page DL: Implications of high-risk pathologic lesions of the breast, (an invited paper). 74th Clinical Congress of the American College of Surgeons, Chicago, IL, October 1988.
18. **Dupont WD**: Statistical inference from sequentially monitored clinical trials, (an invited paper). Third Annual Symposium of the International Institute for Theoretical Cardiology, Greenville, NC, November 1988.
19. **Dupont WD** and Page DL: Histopathologic definition of high risk breast lesions, (an invited paper). Seventeenth International Congress of Radiology, Paris, France, July 1989.
20. **Dupont WD** and Page DL: Does replacement estrogen therapy increase breast cancer risk? (an invited paper). 17^{es} Journées Sur La Fertilité et L'Orthogénie, Paris, France, November 1989.
21. **Dupont WD** and Page DL: What are the frontiers of research in benign breast disease? (an invited paper). 17^{es} Journées Sur La Fertilité et L'Orthogénie, Paris, France, November 1989.
22. **Dupont WD** and Plummer WD: Power and sample size calculations: A review and computer program, Eleventh Annual Meeting of The Society for Clinical Trials, Toronto, ON, May, 1990. *Controlled Clin Trials*, 1990; 11:301.
23. **Dupont WD**: Statistical issues in assessing prognostic indices for breast cancer, (an invited paper). The American Joint Committee on Cancer, Chicago, IL, June 1990.
24. **Dupont WD** and Page DL: Breast cancer risk, family history, and epithelial hyperplasia. 15th International Cancer Congress, Hamburg, Germany, August 1990.
25. Page DL, **Dupont WD**, and other discussants. Breakout sessions on the limits of early detection of breast cancer, the definitions of precancerous breast lesions, the effects of tamoxifen on high risk lesions, and the incidence of premalignant lesions. NCI workshop on Emerging Concepts and Strategies in Breast Cancer, St. Michaels, MD, September 1990.
26. **Dupont WD**: Breast cancer risk associated with estrogen replacement therapy. Presentation made to the FDA Fertility and Maternal Health Drugs Advisory Committee, Washington, DC, June 1991.
27. **Dupont WD** and Page DL: Hormone replacement therapy and breast cancer, (an invited paper). Symposium on hormone replacement therapy sponsored by the Royal Medical Society. London, England, September 1991.
28. **Dupont WD**: Benign high-risk and premalignant diseases of the breast, (an invited paper). Clinical Congress of the American College of Surgeons, Chicago, IL, October 1991.
29. **Dupont WD**: Epidemiology of benign breast disease and risk factors for breast cancer, (an invited paper). Quartrième Journée Scientifique: Collège de Gynécologie Médicale de Paris — Ile-de-France, Paris, France, January 1992.

30. **Dupont WD:** Benign proliferative diseases of the breast: Histologic definitions and breast cancer risks, (an invited paper). International Course of Diagnostic Imaging and Interventional Radiology (CARVAT), Rome, Italy, January 1992.
31. **Dupont WD:** Estrogen replacement therapy and breast cancer risk in women with a history of benign mammary dysplasia, (an invited paper). International Course of Diagnostic Imaging and Interventional Radiology (CARVAT), Rome, Italy, January 1992.
32. **Dupont WD:** Premalignant markers of increased breast cancer risk, (an invited paper). 83rd Annual Meeting of the American Association for Cancer Research, San Diego, CA, May 1992.
33. **Dupont WD, Parl FF, Hartmann WH, and Brinton LA:** Breast cancer risk associated with proliferative breast disease. 25th Annual Meeting for the Society for Epidemiologic Research. Minneapolis, MN, June 1992. *Am J Epidemiol*, 1992; 136:964.
34. **Dupont WD** (an invited participant): Workshop on HRT and breast cancer risk: International Medical Benefit Risk Foundation. London, England, 1992.
35. **Dupont WD:** Premalignant markers of increased breast cancer risk, (an invited paper). Gordon Research Conference on Mammary Gland Biology. New London NH, June 1993. *Science*, 1993; 259:1190.
36. **Dupont WD** and Page DL: Epidemiology of benign breast disease and risk factors for breast cancer, (an invited paper). American Cancer Society: National Conference on Breast Cancer. Boston, MA, August 1993.
37. **Dupont WD:** HRT and breast cancer. Wyeth-Ayerst MCS and Regional Clinical Associates Meeting. Frazer, PA, October 1993.
38. **Dupont WD:** Breast Cancer: Who's at risk? Wyeth-Ayerst Women's Health Seminar. Princeton, NJ, November 1993.
39. **Dupont WD:** Premalignant markers of breast cancer risk. (Invited plenary address Conférence du Président) Symposium International de Biologie et Pathologie du Tissu Mammaire. Paris, France, December 1993.
40. **Dupont WD:** HRT and breast cancer. Wyeth-Ayerst International Symposium on Contemporary Approaches to Managing Estrogen Deficiency. Santiago, Chile, April 1994.
41. **Dupont WD.** Oral HRT and breast cancer. Laboratoire Innothera Workshop: THS per os: contre-indications? Paris, France, September 1994.
42. **Dupont WD.** Estrogen replacement therapy after breast cancer. (an invited paper). XIV World Congress of the International Federation of Gynecology and Obstetrics. Montreal, Canada, September 1994.

43. **Dupont WD.** Hormones and breast cancer, (an invited paper). Xi^e Journées: Actualités en Gynécologie-Obstétrique. Collège de Gynécologie Médicale du Sud-Est. Nice, France, February 1995.
44. **Dupont WD.** Hormones et cancer, (an invited paper). Le Collège de Gynécologie Rhône-Alpes. Lyon, France, February 1995.
45. **Dupont WD.** Hormonal replacement therapy and breast cancer risk, (an invited paper). National Consortium of Breast Centers. Nashville, TN, April 1995.
46. **Dupont WD.** Breast cancer risk associated with complex and non-complex fibroadenoma, (an invited paper). International Symposium on Breast Pathology. São Paulo, Brazil, June 1995.
47. **Dupont WD.** Breast cancer risk associated with proliferative breast disease and atypical hyperplasia, (an invited paper). International Symposium on Breast Pathology. São Paulo, Brazil, June 1995.
48. **Dupont WD.** Breast Cancer risk associated with long-term hormone replacement therapy, (an invited paper). International Symposium on Breast Pathology. São Paulo, Brazil, June 1995.
49. **Dupont WD.** Hormonal replacement therapy after breast cancer: Arguments in favor of clinical studies, (an invited paper). International Symposium on Breast Pathology. São Paulo, Brazil, June 1995.
50. **Dupont WD.** Benefits and risks of HRT with cyclic or continuous regimes: The breast cancer risk controversy, (an invited paper). Wyeth-Ayerst symposium on Individualized HRT with Cyclic or Continuous Regimes. European Consensus Development Conference on Menopause. Montreux, Switzerland, September 1995.
51. **Dupont WD.** Epidemiologic and Biostatistical Methods. Part I - Introduction. National Breast Cancer Coalition. Project LEAD. Nashville, TN, December 1995.
52. **Dupont WD.** Epidemiologic and Biostatistical Methods. Part III -Clinical Trials. National Breast Cancer Coalition. Project LEAD. Nashville, TN, December 1995.
53. **Dupont WD.** Hormonal replacement therapy and breast cancer risk. Cancer Institute of New Jersey (an invited paper in the Institute's Distinguished Lecture Series) New Brunswick, NJ, October 1996.
54. **Dupont WD.** Hormone replacement therapy and the risk of breast cancer. 14th Annual International Breast Cancer Conference. Miami Beach, FL, 1997.
55. **Dupont WD.** Controversies in hormonal replacement therapy 21st Central American Congress of Obstetrics and Gynecology. Managua, Nicaragua, 1997.

56. **Dupont WD.** Hormonal replacement therapy in patients with breast cancer 21st Central American Congress of Obstetrics and Gynecology. Managua, Nicaragua, 1997.
57. **Dupont WD.** Le THS chez la femme à risque de cancer du sein. 20th meeting of the Association Française pour l'Étude de la Ménopause. Paris, France, November 1999.
58. **Dupont WD.** Incidence of breast cancer in high risk patients receiving HRT. RAP-Risk and Prevention Conference. Paris, France, February 2000.
59. **Dupont WD, Plummer WD.** The PS Program for Sample Size and Power Calculations. JSM 2001. Atlanta, Georgia, USA, August 5, 2001.
60. **Dupont WD, Plummer WD.** Density distribution sunflower plots. JSM 2003. San Francisco, California, USA, August 2003.
61. **Dupont WD.** TGF- β 1 T29 \rightarrow C polymorphism and breast cancer risk in women with and without proliferative disease. N.C.I. Breast SPORE Roundtable Meeting. Boston, MA, November 2003.
62. Gobbi H, **Dupont WD**, Parl FF, Schuyler PA, Plummer WD, Olson SJ, Page DL: Breast cancer risk associated with estrogen receptor expression in epithelial hyperplasia lacking atypia. 12th SPORE Investigator's Workshop. Baltimore, MD, July, 2004.
63. **Dupont WD.** Teaching Intermediate-level biostatistics to clinicians using general statistical software packages. Section on Teaching of Statistics in the Health Sciences Round Table Luncheon. Joint Statistical Meetings, Toronto, Ontario, Canada, August 2004.
64. **Dupont WD.** Density distribution sunflower plots in Stata 8. Third North American Stata Users Group Meeting. Boston, MA. August 2004.
65. Sanders ME, Parl FF, Page DL, Roodi N, Schuyler PA, Plummer WD, **Dupont WD:** Relationship of the transformation growth factor- β 1 T29 \rightarrow C polymorphism to breast cancer risk in women with, and without, proliferative breast disease. San Antonio Breast Cancer Symposium, December 2004. *Breast Cancer Research and Treatment* 2004; 88: S162.
66. Breyer J, Schuyler P, Elmore B, Yaspan B, Bradley K, Page D, **Dupont W**, Smith J: Genetic data from archival tissue. 14th SPORE Investigators' Workshop. July 2006.
67. **Dupont WD**, Breyer JP, Bradley KM, Schuyler PA, Plummer WD, Sanders ME, Page DL, Smith JR. Effect of protein phosphatase 2A subunit gene haplotype and proliferative breast disease on breast cancer risk. San Antonio Breast Cancer Symposium, December 2008. *Cancer Res* 2009;69 (2 Suppl.): 229S

THESES AND STUDENT PAPERS

1. **Dupont WD:** An adaptive automatic integration algorithm based on Simpson's rule, M.Sc. thesis, McGill University, 1971.

2. **Dupont WD:** A multiple risk model with dependent fates, Technical Paper #501, Biostatistics Department, The Johns Hopkins University, 1975.
3. **Dupont WD:** A stochastic method for estimating animal abundance from catch-effort data, Ph.D. Thesis, The Johns Hopkins University, 1976.

NATIONAL TELEVISION

1. Fibroadenoma and breast cancer
 - i) NBC Nightly News, July 6, 1994
 - ii) CBS Evening News, July 6, 1994
 - iii) CBS This Morning, July 7, 1994
 - iv) CNN News from Medicine, July 7, 1994

LETTERS TO THE EDITOR

1. **Dupont WD:** Making causal inferences from observational data, *Biometrics*, December 1978; 34:713-14.
2. **Dupont WD:** Case-control studies of estrogens and endometrial cancer, *N Engl J Med*, March 1979; 300:495.
3. **Dupont WD:** Bias, maximum likelihood estimators, and sequential clinical trials, *Controlled Clin Trials*, September 1984; 5:275-7.
4. **Dupont WD** and Page DL: Fibrocystic breast non-disease, *N Engl J Med*, 1985; 312:1258.
5. **Dupont W**, Page D: A retrospective cohort study of women with benign breast disease - interactions between histologic and other factors on breast-cancer risk, *Am J Epidemiol* 1985; 122 (3): 516-516.
6. **Dupont WD:** Randomized vs. historical trials: are the benefits worth the cost? *Am J Epidemiol*, August 1986; 124:340-1.
7. **Dupont W**, Page D: Influence of exogenous estrogens and proliferative breast disease on breast-cancer risk, *Am J Epidemiol*, 1987; 126 (4): 735
8. **Dupont WD:** The EC-IC bypass study, *N Engl J Med*, October 1987; 317:1031.
9. **Dupont WD:** Sensitivity of Fisher's exact test to minor perturbations in 2x2 contingency tables — Author's Reply, *Stat Med*, 1989; 8:244-5.
10. **Dupont WD** and Page DL: Influence of exogenous estrogens, proliferative breast disease and other variables on breast cancer risk — Author's Reply, *Cancer*, 1990; 65:1261-2.
11. **Dupont WD:** Growth hormone for the elderly, *N Engl J Med*, 1990; 323:1562.

12. **Dupont WD**: Estrogen replacement therapy and risk of breast cancer, *JAMA*, 1991; 265:1824.
13. Page DL and **Dupont WD**: Proliferative breast disease: Diagnosis and implications, (Technical Comments) *Science*, 1991; 253(5022): 915-6.
14. **Dupont WD** and Page DL: Estrogen and breast cancer — Author's reply, *Arch Intern Med*, 1991; 151:1882-4.
15. **Dupont WD** and Page DL: Meta-analyses of breast cancer risk associated with estrogen replacement therapy — Author's reply, *Arch Intern Med*, 1992; 152:1090-3.
16. **Dupont WD**: The breast implant controversy, *N Engl J Med*, 1993; 328:733.
17. **Dupont WD**: Breast cancer and hormone-replacement therapy, *N Engl J. Med*, 1995; 333:1356-8.
18. **Dupont WD**: Comparison of ganisetron, onansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer. *Cancer*, 1996; 78:2451.
19. **Dupont WD** and Plummer WD: PS power and sample size program available for free on the Internet. *Controlled Clin Trials*, 1997; 18:274.
20. Edwards KM and **Dupont WD**: Intranasal Influenzavirus Vaccine in Children. *N Engl J Med*, 1998; 339:922.

PAPERS IN PROFESSIONAL JOURNALS

1. Latham RH, Kaiser AB, **Dupont WD**, and Dan BB: Chronic pulmonary histoplasmosis following the excavation of a bird roost. *Am J Med*, 1980; 68(4):504-8.
2. **Dupont WD**, Rogers LW, VanderZwaag R, and Page DL: The epidemiologic study of anatomic markers for increased risk of mammary cancer. *Pathol Res Pract*, 1980; 166:471-80.
3. Kampmeier RH, Sweeney A, Quinn RW, Lefkowitz LB, and **Dupont WD**: Survey of 251 patients with acute syphilis treated in the collaborative penicillin study of 1943 to 1950. *Sex Transm Dis*, 1981; 8:266-79.
4. Dean RH, Kieffer RW, Smith BM, Oates JA, Nadeau JH, Hollifield JW, and **Dupont WD**: Renovascular hypertension: Anatomic and renal function changes during therapy. *Arch Surg*, 1981; 116:1408-15
5. Brorson L, Reece S, **Dupont W**, Woosley RL, Shand D, and Smith R: Effects of concentration and steric configuration of propranolol on AV conduction and ventricular repolarization in the dog. *J Cardiovasc Pharmacol*, 1981; 3:692-703.

6. Page DL, **Dupont WD**, Rogers LW, and Landenberger M: Intraductal carcinoma of the breast. Follow-up after biopsy only. *Cancer*, 1982; 49:751-8.
7. Parl FF and **Dupont WD**: A retrospective cohort study of histologic risk factors in breast cancer patients. *Cancer*, 1982; 50:2410-6.
8. **Dupont WD**: Sequential stopping rules and sequentially adjusted P values: Does one require the other? *Controlled Clin Trials*, 1983; 4:3-10.
9. **Dupont WD**: Rejoinder: statistical inference from trials with sequential stopping rules. *Controlled Clin Trials*, 1983; 4:27-33.
10. **Dupont WD**: A stochastic catch-effort method for estimating animal abundance. *Biometrics*, 1983; 39:1021-33.
11. Dean RH, Kreuger TC, Whiteneck JM, **Dupont B**, Foster JH, Smith BM, Hollifield JW, and Oates JA: Operative management of renovascular hypertension: results after a follow-up of fifteen to twenty-three years. *J Vasc Surg*, 1984; 1:234-42.
12. Halter SA, Fraker LD, Parmenter M, and **Dupont WD**: Carcinoembryonic antigen expression and patient survival in carcinoma of the breast. *Oncology*, 1984; 41:297-302.
13. Dean RH, Keyser JE, **Dupont WD**, Nadeau JH, and Meacham PW: Aortic and renal vascular disease: Factors affecting the value of combined procedures. *Ann Surg*, 1984; 200:336-44.
14. Parl FF, Schmidt BP, **Dupont WD**, and Wagner RK: Prognostic significance of estrogen receptor status in breast cancer in relation to tumor stage, auxiliary node metastasis and histopathologic grading. *Cancer*, 1984; 54:2237-42.
15. **Dupont WD** and Page DL: Risk factors for breast cancer in women with proliferative breast disease. *N Engl J Med*, 1985; 312:146-51.
16. Page DL, **Dupont WD**, Rogers LW, and Rados MS: Atypical hyperplastic lesions of the female breast: A long-term follow-up study. *Cancer*, 1985; 55:2698-2708.
17. Dean RH, Englund R, **Dupont WD**, Plummer WD, Pierce R, and Ezell C: Retrieval of renal function by revascularization: study of preoperative outcome predictors. *Ann Surg*, 1985; 202:367-75.
18. **Dupont WD**: Randomized versus historical clinical trials: Are the benefits worth the cost? *Am J Epidemiol*, 1985; 122:940-46.
19. Greer JP, Kinney MC, Cousar JB, Flexner JM, **Dupont WD**, Graber SE, Greco FA, Collins RD, and Stein RS: Lymphocyte-depleted Hodgkin's disease: a clinicopathologic review of 25 patients. *Am J Med*, 1986; 81:208-14.
20. Page DL, **Dupont WD**, and Rogers LW: Breast cancer risk of lobular-based hyperplasia after biopsy: 'Ductal' pattern lesions. *Cancer Detect Prev*, 1986; 9:441-8.

21. **Dupont WD**: Sensitivity of Fisher's exact test to minor perturbations in 2 x 2 contingency tables. *Stat Med*, 1986; 5:629-35.
22. Page DL and **Dupont WD**: Are breast cysts a premalignant marker? *Eur J Cancer and Clin Oncol*, 1986; 22:635-6.
23. **Dupont WD** and Page DL: Breast cancer risk associated with proliferative disease, age at first birth, and a family history of breast cancer. *Am J Epidemiol*, 1987; 125:769-79.
24. Gordon L, Wood AJJ, Koshakji RP, Wilkinson GR, **Dupont WD**, and Wood M: Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. *Anesthesiology*, 1987; 67:225-30.
25. Page DL, **Dupont WD**, and Rogers LW: Ductal involvement by cells of atypical lobular hyperplasia in the breast: A long-term follow-up study of cancer risk. *Hum Pathol*, 1988; 19:201-7.
26. Kronenberg MW, Uetrecht JP, **Dupont WD**, Davis MH, Phelan BK, and Friesinger GC: Intrinsic left ventricular contractility in normal subjects. *Am J Cardiol*, 1988; 61:621-7.
27. Page DL and **Dupont WD**: Histopathologic risk factors for breast cancer in women with benign breast disease. *Semin Surg Oncol*, 1988; 4:213-7.
28. **Dupont WD**: Power calculations for matched case-control studies. *Biometrics*, 1988; 44:1157-68.
29. Kossoy LR, Hill GA, Herbert CM, Brodie BL, Dalglisch CS, **Dupont WD**, and Wentz AC: Therapeutic donor insemination: The impact of insemination timing with the aid of a urinary luteinizing hormone immunoassay. *Fertil Steril*, 1988 49:1026-9.
30. King JC, Haugh CJ, **Dupont WD**, Wright PF, and Edwards KM: Laboratory and epidemiologic assessments of a recent influenza B outbreak. *J Med Virol*, 1988; 25:361-8.
31. **Dupont WD** and Page DL: Cancer risk in benign breast disease. *Reviews on Endocrine-Related Cancer*, 1988; 32:5-9.
32. **Dupont WD**, Page DL, Rogers LR, and Parl FF: Influence of exogenous estrogens, proliferative breast disease and other variables on breast cancer risk. *Cancer*, 1989; 63:948-57.
33. Antman EM, **Dupont WD**, Bonalsky J, et al.: Early treatment with intravenous metoprolol for suspected acute myocardial infarction: A phase IV United States trial. *Int J Cardiol*, 1989; 23:185-97.
34. **Dupont WD** and Page DL: Relative risk of breast cancer varies with time since diagnosis of atypical hyperplasia. *Hum Pathol*, 1989; 20:723-5.
35. **Dupont WD**: Converting relative risks to absolute risks: A graphical approach. *Stat Med*, 1989; 8:641-51.

36. Tham KT, **Dupont WD**, Page DL, Gray GF, and Rogers LW: Micro-papillary hyperplasia with atypical features in female breasts, resembling gynecomastia. *Progress in Surgical Pathology*, 1989; 10:101-9.
37. Jensen RA, Page DL, **Dupont WD**, and Rogers LW: Invasive breast cancer risk in women with sclerosing adenosis. *Cancer*, 1989; 64:1977-83.
38. Parl FF, Cavener DR, and **Dupont WD**: Genomic DNA analysis of the estrogen receptor gene in breast cancer. *Breast Cancer Res Treat*, 1989; 14:57-64.
39. Edwards KM, Bradley RB, Decker MD, Palmer PS, Van Savage J, Taylor JC, **Dupont WD**, Hager CC, and Wright PF: Evaluation of a new highly purified pertussis vaccine in infants and children. *J Infect Dis*, 1989; 160:832-7.
40. Page DL and **Dupont WD**: New biologic prognostic factors in breast cancer: The article reviewed. *Oncology*, 1989; 3:58.
41. **Dupont WD** and Plummer WD: Power and sample size calculations: A review and computer program. *Controlled Clin Trials*, 1990; 11:116-28.
42. **Dupont WD** and Page DL: L'oestrogénothérapie substitutive accroît-elle le risque de cancer du sein? *Contraception Fertilité Sexualité*, 1990; 18:115-9.
43. Page DL and **Dupont WD**: Premalignant conditions and markers of elevated risk in the breast and their management. *Surg Clin North Am*, 1990; 70:831-51.
44. Page DL and **Dupont WD**: Anatomic markers of human premalignancy and risk of breast cancer. *Cancer*, 1990; 66:1326-35.
45. Simpson JF, Page DL, and **Dupont WD**: Apocrine adenosis — A mimic of mammary carcinoma. *Surg Pathol*, 1990; 3:289-99.
46. **Dupont WD** and Page DL: Menopausal estrogen replacement therapy and breast cancer. *Arch Intern Med*, 1991; 151:67-72.
47. Novak JM, Scribner KT, **Dupont WD**, and Smith MH: Catch-effort estimation of white-tailed deer population size. *Journal of Wildlife Management*, 1991; 55:31-8.
48. **Dupont WD**: Ethics and statistics in randomized clinical trials — comment. *Stat Science*, 1991; 6:69-71.
49. Page DL and **Dupont WD**: Histologic indicators of breast cancer risk. *Bulletin of the American College of Surgeons*, 1991; 76:16 – 23.
50. Page DL, Kidd TE, **Dupont WD**, Simpson J, and Rogers LW: Lobular neoplasia of the breast: Higher risk for subsequent invasive cancer predicted by more extensive disease. *Hum Pathol*, 1991; 22:1232-9.

51. Yaich L, **Dupont WD**, Cavener DR, and Parl FF: Analysis of the PvuII restriction fragment-length polymorphism and exon structure of the estrogen receptor gene in breast cancer and peripheral blood. *Cancer Res*, 1992; 52:77-83.
52. Page DL and **Dupont WD**: Benign breast disease: Indicators of increased breast cancer risk. *Cancer Detect Prev*, 1992; 16:93-7.
53. Page DL and **Dupont WD**: Indicators of increased breast cancer risk in humans. *J Cell Biochem*, 1992; 16G:175-182.
54. Page DL and **Dupont WD**: Breast cancer angio-histogenesis: Through a Narrow Window. *J Natl Cancer Inst*, 1992; 84:1850-1.
55. **Dupont WD**, Parl FF, Hartmann WH, Brinton LA, et al.: Breast cancer risk associated with proliferative breast disease and atypical hyperplasia. *Cancer*, 1993; 71:1258-65.
56. Page DL and **Dupont WD**: Anatomic indicators (histologic and cytologic) of increased breast cancer risk. *Breast Cancer Res Treat*, 1993; 28:157-66.
57. Jensen RA, **Dupont WD**, and Page DL: Diagnostic criteria and cancer risk of proliferative breast lesions. *J Cell Biochem*, 1993; 17G:59-64.
58. Edwards KM, **Dupont WD**, Westrich KM, Plummer WD, Palmer PS, and Wright PF: A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. *J Infect Dis*, 1994; 169:68-76.
59. O'Malley FP, Page DL, Nelson EH, and **Dupont WD**: Ductal carcinoma in-situ of the breast with apocrine cytology: Definition of a borderline category. *Hum Pathol*, 1994; 25:164-8.
60. Caleffi M, Teague MW, Jensen RA, Vnencak-Jones CL, **Dupont WD**, and Parl FF: p53 gene mutations and steroid receptor status in breast cancer: Clinicopathologic correlations and prognostic assessment. *Cancer*, 1994; 73:2147-56.
61. Dalton LW, Page DL, and **Dupont WD**: Histologic grading of breast carcinoma: A reproducibility study. *Cancer*, 1994; 73:2765-70.
62. **Dupont WD**, Page DL, Parl FF, Vnencak-Jones CL, Plummer WD Jr., Rados MS, and Schuyler PA: Long-term breast cancer risk in women with fibroadenoma. *N Engl J Med*, 1994; 331:10-5.
63. Simpson JF, O'Malley FP, **Dupont WD**, and Page DL: Heterogeneous expression of nm23 gene product in non-invasive breast carcinoma. *Cancer*, 1994; 73:2352-8.
64. O'Malley FP, Vnencak-Jones CL, **Dupont WD**, Parl F, Manning S, and Page DL: p53 mutations are confined to the comedo type ductal carcinoma in-situ of the breast: Immunohistochemical and sequencing data. *Lab Invest*, 1994; 71:67-72.
65. **Dupont WD**: Evidence of efficacy of mammographic screening for women in their forties. *Cancer*, 1994; 74:1204-6.

66. Roodi N, Bailey LR, Kao WY, Verrier CS, Yee CJ, **Dupont WD**, and Parl FF: Estrogen receptor gene analysis in estrogen receptor-positive and receptor-negative primary breast cancer. *J Natl Cancer Inst*, 1995; 87:446-51.
67. Page DL, **Dupont WD**, Rogers LW, Jensen RA, and Schuyler PA: Continued local recurrence of carcinoma 15 – 25 years after a diagnosis of low grade ductal carcinoma in-situ of the breast treated only by biopsy. *Cancer*, 1995; 76:1197-200.
68. Page DL, **Dupont WD**, and Jensen RA: Papillary apocrine change of the breast: Associations with atypical hyperplasia and risk of breast cancer. *Cancer Epidemiol Biomark Prev*, 1996; 5:29-32.
69. Vnencak-Jones CL, Phillips JA, Janco RL, Cohen MP, **Dupont WD**, Kazazian HH, and Rossitier JP: Analysis of factor VIII gene inversion mutations in 166 unrelated hemophilia A families: frequency and utility in genetic counseling. *Hemophilia*, 1996; 2:18-23.
70. **Dupont WD** and Plummer WD: Understanding the relationship between relative and absolute risk. *Cancer*, 1996; 77:2193-9.
71. Page DL, Salhany KE, Jensen RA, and **Dupont WD**: Subsequent breast carcinoma risk after biopsy with atypia in a breast papilloma. *Cancer*, 1996; 78:258-66.
72. Carmichael LC, Dorinsky PM, Higgins SB, Bernard GR, **Dupont WD**, Swindell B, and Wheeler AP: Diagnosis and therapy of Acute Respiratory Distress Syndrome in adults: An international survey. *J Critical Care*, 1996; 11:9-18.
73. Bernard GR, Wheeler AP, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson WJ, Wright PE, Christman BW, **Dupont WD**, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. *N Engl J Med*, 1997; 336:912-8.
74. Kasami M, Vnencak-Jones CL, Manning S, **Dupont WD**, and Page DL: Loss of heterozygosity and microsatellite instability in breast hyperplasia: No obligate correlation of these genetic alterations with subsequent malignancy. *Am J Pathol*, 1997; 150:1925-32.
75. Page DL, **Dupont WD**, Holt JT, and Jensen RA: Directions and associations in premalignant breast disease: the important role of non-comedo ductal carcinoma in situ, *Endocrine-Related Cancer*, 1997; 4:105-12.
76. Page DL, Johnson JE, and **Dupont WD**: Probabilistic approach to reporting of fine-needle aspiration cytology of the breast, *Cancer (Cancer Cytopathology)*, 1997; 81:6-9.
77. Bailey LR, Roodi N, Verrier CS, Yee CJ, **Dupont WD**, and Parl FF: Breast Cancer and CYP1A1, GSTM1, and GSTT1 polymorphisms: evidence of a lack of association in Caucasians and African Americans. *Cancer Res*, 1998; 58: 65-70.
78. Page DL, **Dupont WD**, Jensen RA, and Simpson JF: When and to what extent do pathologists agree?, *J Natl Cancer Inst*. 1998; 90: 88-9.

79. Kasami M, Vnencak-Jones CL, Manning S, **Dupont WD**, Jensen RA, and Page DL: Monoclonality in fibroadenomas with complex histology and phyllodol features. *Breast Cancer Res Treat*, 1998; 50: 185-91.
80. Bailey LR, Roodi N, **Dupont WD**, and Parl FF: Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid *receptor* status in breast cancer. *Cancer Res*, 1998; 58: 5038-41.
81. **Dupont WD** and Plummer WD: Power and sample size calculations for studies involving linear regression. *Controlled Clin Trials*, 1998; 19: 589-601.
82. Page DL, **Dupont, WD**: Benign breast diseases and premalignant breast disease. *Arch Pathol Lab Med*, 1998; 122: 1048-50
83. **Dupont WD**, Page DL, Parl FF, Plummer WD, Schuyler PA, Kasami M, and Jensen RA: Estrogen replacement therapy in women with a history of proliferative breast disease. *Cancer*, 1999; 85: 1277-83.
84. Arons, MM, Wheeler, AP, Bernard GR, Christman BW, Russell JA, Schein R, Summer WR, Steinberg KP, Fulkerson W, Wright P, **Dupont WD**, Swindell BB: Effects of ibuprofen on the physiology and survival of hypothermic sepsis. *Critical Care Medicine*, 1999; 27: 699-707.
85. **Dupont, WD**, Plummer, WD: Exact confidence intervals for odds ratios from case-control studies. *Stata Technical Bulletin*. 1999; STB-52: 12-14.
86. Gobbi H, **Dupont WD**, Simpson JF, Plummer WD, Schuyler PA, Olson SJ, Arteaga CL, and Page DL: Transforming growth factor- β and breast cancer risk in women with mammary epithelial hyperplasia. *J Natl Cancer Inst.*, 1999; 91: 2096-101.
87. Dalton LW, Pinder SE, Elston CE, Ellis IO, Page DL, **Dupont WD**, Blamey RW. Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement. *Mod Pathol*, 2000; 13(7): 730-5.
88. Gobbi H, Arteaga CL, Jensen RA, Simpson JF, **Dupont WD**, Olson SJ, Schuyler PA, Plummer WD, and Page DL: Loss of expression of transforming growth factor β type II receptor correlates with high tumor grade in human breast in situ and invasive carcinomas. *Histopathology*, 2000; 36: 168-77.
89. Kasami M, Gobbi H, **Dupont WD**, Simpson JF, Page DL, and Vnencak-Jones CL: Androgen receptor CAG repeat lengths in ductal carcinoma in situ of breast, longest in apocrine variety. *The Breast*, 2000; 9: 23-7.
90. Mangialardi RJ, Martin GS, Bernard GR, Wheeler AP, Christman BW, **Dupont WD**, Higgins SB, and Swindell BB: Hypoproteinemia predicts ARDS development, weight gain and death in patients with sepsis. *Critical Care Medicine*, 2000; 28(9): 3137-45.
91. Page DL, Jensen RA, Simpson JF, **Dupont WD**. Historical and epidemiological background of human premalignant breast disease. *J Mammary Gland Bio and Neoplasia*, 2000; 5(4): 341-9.

92. Peebles RS, Carpenter CT, **Dupont WD**, Loyd JE. Mediastinal fibrosis is associated with human leukocyte antigen-A2. *Chest*, 2000; 117(2): 482-5.
93. Carter BA, Page DL, Schuyler P, Parl FF, Simpson JF, Jensen RA, **Dupont WD**: No elevation in long-term breast carcinoma risk for women with fibroadenomas that contain atypical hyperplasia. *Cancer*, 2001; 92(1); 30-6.
94. Mommers EC, Page DL, **Dupont WD**, Schuyler P, et al. Prognostic value of morphometry in patients with normal breast tissue or usual ductal hyperplasia of the breast. *Int J Cancer*, 2001; 95: 282-5.
95. Neuzil KM, **Dupont WD**, Wright PF, and Edwards KM. Efficacy of inactivated and cold-adapted vaccines against influenza A infection. *Pediatr Infect Dis J.*, 2001; 20(8); 733-40.
96. Ritchie MD, Hahn LW, Roodi N, Bailey R, **Dupont WD**, Parl FF, Moore JH: Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. *Am J Hum Genet*, 2001;69:138-47.
97. Martin GS, Mangialardi RJ, Wheeler AP; **Dupont WD**, Morris JA, Bernard GR: Albumin and furosemide therapy in hypoproteinemic patients with acute lung injury. *Critical Care Medicine*, 2002;30:2175-82.
98. Page DL, Schuyler PA, **Dupont WD**, Jensen RA, Plummer WD, Simpson JF: Atypical lobular hyperplasia as a unilateral predictor of breast cancer risk: a retrospective cohort study. *Lancet*, 2003;361:125-9.
99. **Dupont WD** and Plummer WD: Density distribution sunflower plots. *Journal of Statistical Software*, 2003; 8:(3)1-5. Posted at <http://www.jstatsoft.org/index.php?vol=8>. Accessed May 15, 2003. See also *Journal of Computational and Graphical Statistics*, 2003;12:247.
100. Page DL, Marcus JN, **Dupont WD**: Premalignant lesions in hereditary breast cancer families. *Am J Oncology Review*, 2003; 2:2-3.
101. Roodi N, **Dupont WD**, Moore JH, Parl FF: Association of homozygous wild-type glutathione S-transferase M1 genotype with increased breast cancer risk. *Cancer Res*, 2004; 64:1233-36.
102. Wagner C, Stone WJ, Koury MJ, **Dupont WD**, Kerine DM: S-adenosylhomocysteine is a more sensitive indicator of renal insufficiency than homocysteine. *Nutrition Res*, 2004; 24:487-94.
103. Neilson EG, Johnson KB, Rosenbloom ST, **Dupont WD**, Talbert D, Giuse DA, Kaiser A, and Miller RA for the Resource Utilization Committee: The impact of peer management on test ordering behavior. *Ann Intern Med*, 2004; 141:196-204.
104. Gobbi H, **Dupont WD**, Parl FF, Schuyler PA, Plummer WD, Olson SJ, Page DL: Breast cancer risk associated with estrogen receptor expression in epithelial hyperplasia lacking atypia and adjacent lobular units. *Int J Cancer*, 2005; 113 (5): 857-59.

105. McLaren BK, Gobbi H, Schuyler PA, Olson SJ, Parl FF, **Dupont WD**, Page DL: Immunohistochemical Expression of Estrogen Receptor in Enlarged Lobular Units with Columnar Alteration in Benign Breast Biopsies: A Nested Case-Control Study. *American Journal of Surgical Pathology*. 2005; 29 (1): 105 - 8.
106. Sanders ME, Schuyler PA, **Dupont WD**, Page DL: Natural history of low grade ductal carcinoma in situ in women treated by biopsy only revealed over 30 years long-term follow-up, *Cancer*, 2005; 103 (12): 2481-4.
107. Rosenbloom ST, Geissbuhler AJ, **Dupont WD**, Giuse DA, Talbert DA, Tierney WM, Plummer WD, Stead WW, Miller RA: Effect of CPOE user interface design on user-initiated access to educational and patient information during clinical care. *J Am Med Inform Assoc*, 2005; 12 (4): 458-73.
108. Collier B, Diaz J, Forbes R, Morris J, May A, Guy J, Ozdas A, **Dupont W**, Jensen G: The impact of a normoglycemic management protocol on clinical outcomes in the trauma intensive care unit. *JPEN J Parenter Enteral Nutr*, 2005; 29 (5): 353 - 59.
109. **Dupont WD**, Plummer WD: Using density distribution sunflower plots to explore bivariate relationships in dense data. *Stata Journal*, 2005; 5(3):371 - 84.
110. McLaren BK, Smith J, Schuyler PA, **Dupont WD**, Page DL: Adenomyoepithelioma: Clinical, histologic, and immunohistologic evaluation of a series of related lesions. *Am J Surg Pathol*, 2005; 29 (10): 1294-1299.
111. Jabs K, Koury MJ, **Dupont WD**, Wagner, C: Relationship between plasma S-adenosylhomocysteine concentration and glomerular filtration rate in children. *Metabolism*, 2006; 55 (2):252-257.
112. Grijalva CG, Craig AS, **Dupont WD**, Bridges CB, Schraq, SJ, Iwane MK, Schaffner W, Edwards KM, Griffin MR: Estimating influenza hospitalizations among children. *Emerg Infect Dis*, 2006;12 (1):103-9.
113. Cohen SM, **Dupont WD**, Courey MS. Quality-of-life impact of non-neoplastic voice disorders: A meta-analysis. *Ann Otol Rhinol Laryngol*. 2006; 115 (2):128-134.
114. Sanders ME, **Dupont WD**, Schuyler PA, Simpson JF, Page DL: Interdependence of radial scar and proliferative disease with respect to invasive breast cancer risk in benign breast biopsies. *Cancer*, 2006; 106 (7): 1453–61.
115. Jensen GL, Silver HJ, Roy MA, Callahan E, Still C, **Dupont W**: Obesity is a risk factor for reporting homebound status among community dwelling older persons. *Obesity*, 2006;14 (3): 509-17.
116. McLaren BK, Schuyler PA, Sanders ME, Jensen RA, Simpson JF, **Dupont WD**, Page DL: Excellent Survival, Cancer Type, and Nottingham Grade following Atypical Lobular Hyperplasia on Initial Breast Biopsy. *Cancer*, 2006;107:1227-33.

117. Cohen SM, Garrett CG, **Dupont WD**, Ossoff RH, Courey MS. Voice-related quality of life in T1 glottic cancer: irradiation versus endoscopic excision. *Ann Otol Rhinol Laryngol.* 2006; 115(8):581-6.
118. Grijalva CG, Weinberg GA, Bennett NM, Staat MA, Craig AS, **Dupont WD**, et al. Estimating the undetected burden of influenza hospitalizations in children. *Epidemiol Infect* 2007; 135 (6): 951-8.
119. Yaspan BL, Breyer JP, Cai Q, Dai Q, Elmore JB, Amundson I, Bradley KM, Shu XO, Gao YT, **Dupont WD**, Zheng W, Smith JR. Haplotype analysis of CYP11A1 identifies promoter variants associated with breast cancer risk. *Cancer Res* 2007;67(12):5673-82.
120. Carroll KN, Gebretsadik T, Griffin MR, **Dupont WD**, Mitchel EF, Wu P, et al. Maternal asthma and maternal smoking are associated with increased risk of bronchiolitis during infancy. *Pediatrics* 2007;119(6):1104-12.
121. Fasig JH, **Dupont WD**, Olson SJ, Lafleur BJ, Cates JM: Steroid Hormone Receptor and COX-2 Expression in Chordoma. *Am J Clin Pathol.* 2007;128(3):375-81.
122. Enriquez R, Griffin MR, Carroll KN, Wu P, Cooper WO, Gebretsadik T, **Dupont WD**, Mitchel EF, Hartert TV. Effect of maternal asthma and asthma control on pregnancy and perinatal outcomes. *J Allergy Clin Immunol.* 2007; 120(3):625-30.
123. Denny JC, Frederick VA, **Dupont WD**, Neilson EG: Increased Hospital Mortality in Patients with Bedside Hippus. *Am J Med.* 2008; 121: 239-245.
124. Kurnik D, Muszkat M, Sofowora GG, Friedman EA, **Dupont WD**, Scheinin M, Wood AJJ, Stein CM. Ethnic and genetic determinants of cardiovascular response to the selective alpha(2)-adrenoceptor agonist dexmedetomidine. *Hypertension.* 2008; 51(2): 406-411.
125. Fasig JH, **Dupont WD**, LaFleur BJ, Olson SJ, Cates JMM. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma. *Neuropathol Appl Neurobiol.* 2008; 34(1): 95-104.
126. Hartert TV, Deng X, Hartman TJ, Wen W, Yang G, Gao Y-T, Jin M, Bai C, Gross M, Roberts LJ, Sheller JR, Christman J, **Dupont W**, Griffin M, Shu XO. The Shanghai Women's Asthma and Allergy Study: Objectives, Design, and Recruitment Results. *Am J Epidemiol.* 2008; 167(11): 1387-96.
127. Cates JMM, Dupont WD, Barnes JW, Edmunds HS, Fasig JH, Olson SJ, Black CC. Markers of epithelial-mesenchymal transition and epithelial differentiation in sarcomatoid carcinoma: utility in the differential diagnosis with sarcoma. *Appl Immunohistochem Mol Morphol* 2008; 16(11): 251-62.
128. Carroll KN, Gebretsadik T, Griffin MR, Wu P, **Dupont WD**, Mitchel EF, Enriquez R, Hartert TV. Increasing burden and risk factors for bronchiolitis-related medical visits in infants enrolled in a state health care insurance plan. *Pediatrics* 2008; 122(1): 58-64.

129. Kurnik D, Friedman EA, Muszkat M, Sofowora GG, Xie HG, **Dupont WD**, Wood AJ, Michael Stein C. Genetic variants in the alpha2C-adrenoceptor and G-protein contribute to ethnic differences in cardiovascular stress responses. *Pharmacogenet Genomics*. 2008;18(9):743-50.
130. Boulos FI, **Dupont WD**, Simpson JF, Schuyler PA, Sanders ME, Freudenthal ME, Page DL. Histologic Associations and Long-Term Cancer Risk in Columnar Cell Lesions of the Breast: A Retrospective Cohort and a Nested Case-Control Study. *Cancer*. 2008;113(9): 2415-21.
131. Wu P, **Dupont WD**, Griffin MR, Carroll KN, Mitchel EF, Gebretsadik T, Hartert TV. Evidence of a causal role of winter virus infection during infancy on early childhood asthma. *Am J Respir Crit Care Med*. 2008; 178(11): 1123-9.
132. Valet RS, **Dupont WD**, Hartert TV. Beta-agonist utilization as an indicator of change in asthma control during pregnancy. *Ann Allergy Asthma Immunol*. In press.
133. **Dupont WD**, Breyer JP, Bradley KM, Schuyler PA, Plummer WD, Sanders ME, Page DL, Smith JR. Effect of protein phosphatase 2A subunit gene haplotype and proliferative breast disease on breast cancer risk. Submitted for publication.

BOOKS

1. **Dupont WD**: *Statistical Modeling for Biomedical Researchers: A Simple Introduction to the Analysis of Complex Data*. Cambridge U.K.: Cambridge University Press, 2002: 2nd printing 2003.
2. **Dupont WD**: *Statistical Modeling for Biomedical Researchers: A Simple Introduction to the Analysis of Complex Data. 2nd Edition*. Cambridge U.K.: Cambridge University Press, 2009.

See also <http://biostat.mc.vanderbilt.edu/dupontwd/wddtext/index.html>
<http://www.cambridge.org/us/catalogue/catalogue.asp?isbn=9780521614801>

BOOK CHAPTERS

1. **Dupont WD** and Page DL: Histologic predictors of breast cancer: Epidemiologic and statistical aspects. In: Ames FC, Blumenschein GR, Montague ED, eds. *Current Controversies in Breast Cancer*, Austin: University of Texas Press, 1984:51-61.
2. **Dupont WD** and Page DL: Relationship to previous breast disease. In: Stoll B.A., ed. *Women at High Risk to Breast Cancer*, Dordrecht, The Netherlands: Kluwer Academic Publishers, 1989:47-56.
3. **Dupont WD** and Page DL: Histo-pathologic definition of high risk breast lesions. In: Bigot JM, Moreau JF, Nahum H, Bellet M, eds. *Radiology*, Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division), 1989:339-44.

4. **Dupont WD** and Page DL: Risk factors for breast carcinoma in women with proliferative breast disease. In: Bland KI and Copeland EM, eds. *The Breast: Comprehensive Management of Benign and Malignant Diseases*, Philadelphia: W.B. Saunders, 1991:292-8.
5. Page DL and **Dupont WD**: Management of the patient at high risk. In: Bland KI and Copeland EM, eds. *The Breast: Comprehensive Management of Benign and Malignant Diseases*, Philadelphia: W.B. Saunders, 1991:1046-52.
6. Page DL, **Dupont WD** and Rodgers W: Concepts of preneoplasia for the goal of cancer prevention. In: *Control of Growth Factors and Prevention of Cancer*, Berlin: Springer-Verlag, 1992:3-11.
7. **Dupont WD** and Page DL: An overview of the effect of oestrogen replacement therapy on breast cancer risk. In: Mann RD, ed. *Hormonal Replacement Therapy and Breast Cancer Risk*, Park Ridge, NJ: Parthenon Publishing, 1992:79-92.
8. Page DL and **Dupont WD**: Estrogen replacement therapy and breast cancer risk. In: Ioannidou-Mouzaka L, Agantis NJ and Karydas I, eds. *Senology, Proceedings of the 7th International Congress on Senology (Breast Diseases), Island of Rhodes, Greece, 3-7 May 1992*, Amsterdam: Elsevier Science Publishers B.V. (Biomedical Division), 1992:41-4.
9. **Dupont WD** and Page DL: Risk factors for breast carcinoma in women with proliferative breast disease. In: Bland KI and Copeland EM, eds. *The Breast: Comprehensive Management of Benign and Malignant Diseases*, Philadelphia: W.B. Saunders, Second Edition, 1998: 427-34.
10. Page DL, Caro SW, and **Dupont WD**: Management of the patient at high risk. In: Bland KI and Copeland EM, eds. *The Breast: Comprehensive Management of Benign and Malignant Diseases*, Philadelphia: W.B. Saunders, Second Edition, 1998: 1453-9.
11. Page DL, Rogers LW, Schuyler PA, **Dupont WD**, and Jensen RA: The natural history of ductal carcinoma in situ of the breast. In: Silverstein MJ, ed. *Ductal Carcinoma in Situ of the Breast*, Philadelphia: Lippincott Williams and Wilkins, Second Edition, 2002:17-21.
12. **Dupont WD** and Page DL: Risk factors for breast carcinoma in women with proliferative breast disease. In: Bland KI and Copeland EM, eds. *The Breast: Comprehensive Management of Benign and Malignant Disorders*, Philadelphia: W.B. Saunders, Third Edition, Vol. 1. 2004: 469-478.
13. Caro SW, Page DL, and **Dupont WD**: Management of the patient at high risk. In: Bland KI and Copeland EM, eds. *The Breast; Comprehensive Management of Benign and Malignant Disorders*, Philadelphia: W.B. Saunders, Third Edition, Vol. 2. 2004: 1499-1510.

BOOK REVIEWS

1. **Dupont WD**: Statistical Methods in Medical Research . 3rd edition. By P. Armitage and G. Berry. *Circulation*, 1996; 94: 3009-10.

2. **Dupont WD:** Review of A Handbook of Statistical Analyses Using Stata, Fourth Edition, by Rabe-Hesketh and Everitt. *The Stata Journal* 2007; 7:245-248.

OTHER PUBLICATIONS

1. **Dupont WD:** A hazard regression method for estimating animal abundance from catch-effort data. *American Statistical Association, 1981 Proceedings of the Statistical Computing Section*, Washington: American Statistical Association, August 1981:45-52.
2. **Dupont WD**, Wright RF, and Plummer WD: *Update: An Interactive Data Entry and Edit Program*. Nashville: CDM Software, 1981:1-102.
3. **Dupont WD** and Plummer WD: CDM: Clinical data management software for interactive data entry and data quality assurance. (New Developments in Statistical Computing) *The American Statistician*, 1985; 39:211.
4. Consensus Meeting, October 3 – 5, 1985, New York: Convened by the Cancer Committee of the College of American Pathologists (**Dupont WD**, participant): Is 'fibrocystic disease' of the breast precancerous? *Arch Pathol Lab Med*, 1986; 110:171-3.
5. **Dupont WD** and Plummer WD: POWER.FOR: A computer program for power and sample size calculations. (New Developments in Statistical Computing) *The American Statistician*, 1991; 45:158.
6. International Medical Benefit/Risk Foundation Workshop (London, October 29 – 30, 1992, **Dupont WD**, participant) Hormone replacement therapy (HRT) and breast cancer risk. *Pharmacoepidemiology and Drug Safety*, 1993; 2:103-5.
7. International Medical Benefit/Risk Foundation (**Dupont WD**, Participant) Workshop on hormone replacement therapy and breast cancer risk — future studies. (Chairman: Professor S. Shapiro) *Pharmacoepidemiology and Drug Safety*, 1993; 2:557-8.
8. Bernard GR, Wheeler AP, Arons MM, Morris PE, Ray HL, Russell JA, Wright PE, and the Antioxidant in ARDS Study Group: A trial of antioxidants N-acetylcysteine and procysteine in the acute respiratory distress syndrome. *Chest*, 1997; 112: 164-72.
9. **Dupont WD:** Teaching intermediate-level biostatistics to clinicians using general statistical software packages. *2004 ASA Proceedings*. Alexandria VA: American Statistical Association 2005:4720-1.

ACADEMIC CITATION FREQUENCY

The following 128 publications by W. D. Dupont and colleagues were listed by the Institute for Scientific Information (Web of Science) as being cited in the literature as of July 9, 2008. There are a total of 7,334 academic publications that have cited these papers. His h-index is 41 (see <http://scientific.thomson.com/products/wos/>).

Number of Times Cited	First Author	Journal	Year	Volume and Pages
934	Dupont	New Eng J Med	1985	312:(3) 146-151
435	Page	Cancer	1985	55:(11) 2698-2708
370	Page	Cancer	1982	49:(4) 751-758
348	Dupont	Arch Intern Med	1991	151:(1) 67-72
334	Dupont	Control Clin Trials	1990	11:(2) 116-128
293	Bernard	New Eng J Med	1997	336:(13) 912-918
245	Dean	Arch Surg	1981	116: (11) 1408-1415
240	Ritchie	Am J Hum Genet	2001	69 (1): 138-147
202	Dupont	Cancer	1993	71:(4) 1258-1265
173	Page	Cancer	1995	76: (7) 1197-1200
170	Edwards	J Infect Dis	1994	169:(1) 68-76
156	Bernard	Chest	1997	112:(1) 164-172
156	Page	Cancer	1990	66:(6) 1326-1335
143	Yaich	Cancer Res	1992	52:(1) 77-83
140	Page	Hum Pathol	1991	22:(12) 1232-1239
119	Dupont	Am J Epidemiol	1987	125:(5) 769-779
117	Roodi	J Natl Cancer Inst	1995	87:(6) 446-451
115	Bailey	Cancer Res	1998	58:(22) 5038-5041
115	Bailey	Cancer Res	1998	58:(1) 65-70
107	Dalton	Cancer	1994	73: (11) 2765-2770
106	Dupont	New Eng J Med	1994	331:(1) 10-15
95	Dupont	Cancer	1989	63:(5) 948-957
90	Caleffi	Cancer	1994	73:(8) 2147-2156
86	Dupont	Control Clin Trials	1997	18:(3) 274-274
83	Parl	Cancer	1984	54:(10) 2237-2242
81	Dupont	Control Clin Trials	1998	19: (6) 589-601
79	Neuzil	Pediatr Infect Dis J	2001	20 (8): 733-740
74	Dean	Ann Surg	1985	202:(3) 367-375
67	Dupont	Hum Pathol	1989	20:(8) 723-725
65	O'Malley	Lab Invest	1994	71:(1) 67-72
59	Arons	Crit Care Med	1999	27:(4) 699-707
56	Page	Lancet	2003	361:(9352) 125-129
56	Parl	Cancer	1982	50:(11) 2410-2416
54	Dean	Ann Surg	1984	200: (3) 336-344
53	Parl	Breast Cancer Res Tr	1989	14:(1) 57-64
50	Dean	J Vasc Surg	1984	1:(1) 234-242
44	Kasami	Am J Pathol	1997	150: (6) 1925-1932
41	Martin	Crit Care Med	2002	30:(10) 2175-2182

Number of Times Cited	First Author	Journal	Year	Volume and Pages
40	Gobbi	Histopathology	2000	36:(2) 168-177
40	Page	Breast Cancer Res Tr	1993	28:(2) 157-166
39	Sanders	Cancer	2005	103:(12) 2481-2484
37	Mangialardi	Crit Care Med	2000	28: (9) 3137-3145
37	Dupont	Biometrics	1988	44: (4) 1157-1168
35	Page	Hum Pathol	1988	19:(2) 201-207
33	Carmichael	J Crit Care	1996	11:(1) 9-18
29	Dupont	Cancer	1999	85:(6) 1277-1283
25	O'Malley	Hum Pathol	1994	25:(2) 164-168
23	Dupont	Biometrics	1983	39: (4) 1021-1033
22	Simpson	Cancer	1994	73: (9) 2352-2358
22	Page	Eur J Cancer Clin On	1986	22:(6) 635-636
21	Page	Cancer Detect Prev	1986	9:(5-6) 441-448
20	Dupont	Control Clin Trials	1983	4:(1) 3-10
19	Page	Cancer Epidemiol Biomark Prev	1996	5:(1) 29-32
19	Kossoy	Fertil Steril	1988	49:(6) 1026-1029
18	Nielson	Ann Intern Med	2004	141 (3): 196-204
18	Dalton	Mod Pathol	2000	13 (7): 730-735
17	Page	Surg Clin North Am	1990	70:(4) 831-851
17	Dupont	Stat Med	1989	8:(6) 641-651
16	Dupont	Cancer	1996	77:(11) 2193-2199
16	Dupont	Am J Epidemiol	1985	122:(6) 940-946
15	Page	Cancer Cytopathology	1997	81:(1) 6-9
14	Dupont	Stat Med	1986	5:(6) 629-635
13	Collier	J Parenter Enteral Nutr	2005	29:(5) 353-358
13	Page	J Natl Cancer Inst	1998	90 (2): 88-89
13	Novak	J Wildlife Manage	1991	55:(1) 31-38
13	Halter	Oncology	1984	41:(5) 297-302
12	Roodi	Cancer Research	2004	64 (4): 1233-1236
12	Carter	Cancer	2001	92 (1): 30-36
12	Page	Science	1991	253:(5022) 915-915
12	Page	Semin Surg Oncol	1988	4:(4) 213-217
11	Grijalva	Emerg Infect Dis	2006	12:(1) 103-109
11	McLaren	Am J Surg Pathol	2005	29:(1) 105-108
11	Page	J Natl Cancer Inst	1992	84:(24) 1850-1851
11	Page	Cancer Detect Prev	1992	16:(2) 93-97
11	Kronenberg	Am J Cardiol	1988	61:(8) 621-627
10	Dupont	Pathol Res Pract	1980	166:(4) 471-480
9	Rosenbloom	J Am Med Inform Assoc	2005	12:(4) 458-473
9	Latham	Am J Med	1980	68: (4) 504-508
8	Kasami	Breast	2000	9 (1): 23-27
8	Peebles	Chest	2000	117 (2): 482-485
7	Cohen	Ann Otol Rhinol Laryngol	2006	115:(2) 128-134
7	Page	J Mammary Gland Biol Neoplasia	2000	5 (4): 341-349

Number of Times Cited	First Author	Journal	Year	Volume and Pages
7	Kaiser	Lancet	1980	2:(8188)252-252
6	Kasami	Breast Cancer Res Tr	1998	50:(2) 185-191
6	Gordon	Anesthesiology	1987	67: (2) 225-230
6	Greer	Am J Med	1986	81: (2) 208-214
6	Kampmeier	Sex Transm Dis	1981	8 (4): 266-279
6	Brorson	J Cardiovasc Pharmacol	1981	3: (4) 692-703
5	Carroll	Pediatrics	2007	119:(6) 1104-1112
5	Cohen	Ann Otol Rhinol Laryngol	2006	115:(8) 581-586
5	Mommers	Int J Cancer	2001	95:(5) 282-285
5	Page	Arch Pathol Lab Med	1998	122: (12) 1048-1050
5	Dupont	JAMA	1991	265:(14) 1824-1824
5	King	J Med Virol	1988	25:(3) 361-368
4	Sanders	Cancer	2006	106:(7) 1453-1461
4	Jabs	Metabolism	2006	55:(2) 252-257
4	Gobbi	Int J Cancer	2005	113:(5) 857-859
4	Wagner	Nutrition Res	2004	24:(7) 487-494
4	Vnencak-Jones	Haemophilia	1996	2:(1) 18-23
4	Sightler	Lab Invest	1994	70:(1)A22-A22
4	Antman	Int J Cardiol	1989	23:(2) 185-197
3	Jensen	Obesity	2006	14:(3) 509-517
3	Dupont	Cancer	1994	74: (4) 1204-1206
3	Simpson	Lab Invest	1993	68:(1)A20-A20
3	Connolly	Lab Invest	1992	66: (1) A13-A13
3	Salhany	Lab Invest	1988	58:(1)A80-A80
2	Yaspan	Cancer Res	2007	67:(12) 5673-5682
2	Enriquez	J Allergy Clin Immunol	2007	120:(3) 625-630
2	McLaren	Cancer	2006	107:(6) 1227-1233
2	McLaren	Am J Surg Pathol	2005	29:(10) 1294-1299
2	Ritchie	Am J Hum Genet Suppl	2000	67: (4) 473
2	Page	Hum Pathol	1993	24:(1)114-114
2	O'Malley	Lab Invest	1993	68:(1)A18-A18
2	Halter	Lab Invest	1981	44:(1)A26-A26
2	Page	Lab Invest	1981	44:(1)A49-A50
2	Dupont	Biometrics	1978	34:(4) 713-713
1	Grijalva	Epidemiol Inf	2007	135:(6) 951-958
1	Edwards	New Eng J Med	1998	339 (13): 922-922
1	Page	Endocr Related Cancer	1997	4: (1) 105-112
1	Dupont	New Eng J Med	1993	328: (10) 733-733
1	Dupont	Contraception Fertilité Sexualité	1990	18: (2) 115-119
1	Dupont	New Eng J Med	1987	317: (16) 1031-1031
1	Dupont	Control Clin Trials	1983	4: (1) 27-33
1	Dupont	New Eng J Med	1979	300: (9) 495-495